Caris Life Sciences to use new investor presentation

Caris Life Sciences will use and post a new investor presentation for the Morgan Stanley Global Healthcare Conference, disclosed as Regulation FD furnished information.

Available on EDGAR 09/14/2026 - 04:41 PM EDT Accepted by SEC EDGAR 09/14/2026 - 04:38 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Caris Life Sciences, Inc. (CAI) reports that, beginning September 14, 2026, company representatives intend to use an investor presentation in meetings with current and potential investors at the Morgan Stanley 24th Annual Global Healthcare Conference and at other investor events.

The investor presentation will be posted on the company’s investor relations website. The disclosure is furnished under Regulation FD and is expressly stated not to be “filed” or incorporated by reference for purposes of the Securities Exchange Act of 1934 or the Securities Act of 1933, except where specifically included in a future filing.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Key Terms

Regulation FD, emerging growth company, Section 18 of the Securities Exchange Act of 1934

3 terms

Regulation FD regulatory

"Item 7.01 Regulation FD Disclosure Beginning on September 14, 2026"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Section 18 of the Securities Exchange Act of 1934 regulatory

"shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Caris Life Sciences (CAI) announce in this Form 8-K?

Caris Life Sciences announced that, starting September 14, 2026, it will use a new investor presentation in meetings with current and potential investors, including at the Morgan Stanley 24th Annual Global Healthcare Conference, and will post the presentation on its investor relations website.

Where can investors access the new Caris Life Sciences (CAI) investor presentation?

The company states it will post the Investor Presentation on its investor relations website at https://investor.carislifesciences.com, where current and potential investors can review the same materials used in conference and other investor meetings.

What is the purpose of Caris Life Sciences (CAI) filing this under Item 7.01 Regulation FD?

The company is furnishing the investor presentation under Regulation FD to provide broad, non-selective disclosure of information it will present at the Morgan Stanley healthcare conference and other investor meetings, ensuring equal access for the market.

Is the Caris Life Sciences (CAI) investor presentation considered filed with the SEC?

No. The company specifies that the information under Item 7.01 is being furnished, not filed, and is not subject to Section 18 of the Exchange Act or incorporated by reference into Securities Act or Exchange Act filings unless expressly stated.

Which conference will feature the new Caris Life Sciences (CAI) investor presentation?

Caris Life Sciences plans to use the investor presentation at the Morgan Stanley 24th Annual Global Healthcare Conference starting September 14, 2026, and also from time to time at other investor conferences and meetings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0002019410FALSENYSETX00020194102026-09-142026-09-140002019410exch:XNAS2026-09-142026-09-140002019410exch:XCHI2026-09-142026-09-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________

FORM 8-K

_______________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 14, 2026

CARIS LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Texas

001-42706

85-2077369

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

750 W. John Carpenter Freeway Suite 800  Irving, TX						75039
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code: (866) 771-8946

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐						Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐						Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐						Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐						Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

CAI

The Nasdaq Stock Market LLC

Common Stock, $0.001 par value

CAI

New York Stock Exchange Texas

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01    Regulation FD Disclosure

Beginning on September 14, 2026, representatives of Caris Life Sciences, Inc. (the “Company”) intend to use an investor presentation (the “Investor Presentation”) in meetings with current and potential investors at the Morgan Stanley 24th Annual Global Healthcare Conference and from time to time at other investor conferences and meetings. The Company will post the Investor Presentation on its investor relations website at https://investor.carislifesciences.com. The website and presentation contents referenced herein are not incorporated into this Current Report on Form 8-K.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 14, 2026
			CARIS LIFE SCIENCES, INC.
			By:			/s/ Luke Power
			Name:			Luke Power
			Title:			Senior Vice President, Chief Financial Officer and Chief Accounting Officer

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2.1 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT 15.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 27.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 16.7 KB